Compare British American Tobacco PLC (BTI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Summit Therapeutics Inc — how do they compare? British American Tobacco PLC trades at $55.93 (market cap $122.36B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: British American Tobacco PLC is far larger — about 10.1× Summit Therapeutics Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BTI | SMMT | |
|---|---|---|
Market Cap | $122.36B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $26.98 |
52-Week Low | $50.39 | $12.55 |
Enterprise Value | $166.31B | $11.39B |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.9, down 2.02% today, with a bearish technical signal overall despite bullish oscillators. The company reported Q2 2026 EPS of $2.25, beating expectations, and maintains strong profitability with a 24.99% net income margin. Recent news highlights its strategic tech partnership with ITC Infotech and workforce restructuring to cut costs.
Outlook is mixed: strong fundamentals and a 66.67% analyst buy rating support upside, but technical weakness and regulatory risks pose challenges. The stock offers value with a P/E of 14.48 and dividend yield, yet faces headwinds from declining combustibles and debt levels.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
